Overview


According to FutureWise analysis the market for AI-based clinical trials solution provider in 2023 is US$ 1.96 billion, and is expected to reach US$ 9.74 billion by 2031 at a CAGR of 22.20%.

The integration of AI-based technologies in preclinical and clinical studies is increasingly being used. This offers companies the potential to improve the precision and efficiency of testing, accelerate drug development, and optimize results. Advanced algorithms can quickly analyze extensive databases of chemical compounds and determine those most likely to bind to a target. Algorithms can also indicate the toxicity of a compound and its potential side effects, permitting researchers to focus their efforts on promising candidates. AI also helps in patient interactions, as it can automate patient procurement and data collection. AI-based analysis can offer insight into participant behavior that tells how researchers design trials.

Patient recruitment is one of the most challenging steps in clinical trials, but by applying artificial intelligence, researchers could significantly improve efficacy and safety while reducing costs. About one in every five clinical trials does not complete its enrollment of participants, mostly due to the complex, stringent, and rigid inclusion criteria researchers must apply and adhere to. Challenges in subject enrollment and matching cause extension of enrollment deadlines to delay the submission of the trial protocols for regulatory approvals. This subsequently caused a deferment of the product launch beyond the initially planned dates. Additionally, selection bias can lead to results that are not generalizable because underrepresented populations may respond poorly to the intervention.

FutureWise Market Research has published a report that provides an insightful analysis AI- based clinical trials solution provider market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, AI- based clinical trials solution provider market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Unlearn.AI, Inc.
  • Saama Technologies
  • Antidote Technologies, Inc.
  • Phesi
  • Deep 6 AI
  • Innoplexus
  • Mendel.ai
  • Intelligencia
  • Median Technologies
  • Symphony AI
  • BioAge Labs, Inc.
  • AiCure, LLC
  • CONSILX
  • DEEP LENS AI
  • Halo Health Systems
  • Pharmaseal
  • Ardigen
  • Trials.Ai
  • Koneksa Health
  • Euretos
  • BioSymetrics
  • Google- Verily
  • GNS Healthcare
  • IBM Watson
  • Exscientia

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in AI- based Clinical Trials Solution Provider Market:

  • In April 2023-Medidata, a Dassault Systemes company, announced that Lambda Therapeutics is implementing Medidata’s cloud-based clinical solutions – Rave EDC, Rave RTSM, and Rave Imaging. This will further augment their clinical trial efficiency by automating and streamlining data management workflows and securely delivering higher-quality data for faster insights. 

  • In March 2023- Exscientia plc collaborated with Charité – Universitätsmedizin Berlin (Charité) to utilize Exscientia's AI-driven precision medicine platform in hematological cancers. Under this collaboration, Charité will assess the potential of Exscientia's precision therapy platform to select better treatments and improve outcomes for patients with hematological cancers. Each patient sample will be evaluated prospectively with a broad panel of marketed drugs, including drugs that may not yet be authorized for the indication, to determine a comparative response profile ex vivo.

The increasing prevalence of AI-based clinical trial solutions and the rising demand for efficient drug development serve as a primary catalyst for the market expected to boost the AI-based clinical trial solution provider market during the forecast period. AI's ability to facilitate various aspects of clinical trials, such as patient recruitment, data analysis, and trial design optimization, accelerates the drug development timeline and reduces costs. By enhancing data-driven decision-making and identifying potential drug candidates more effectively, AI empowers pharmaceutical companies and researchers to bring innovative therapies to patients faster, addressing critical medical needs and driving the growth of the AI-based clinical trial solutions market. For instance, AiCure, a company specializing in AI-powered patient monitoring and adherence software, has recently unveiled a collaboration with BioClinica, a clinical trial management services provider. This partnership aims to integrate AiCure's technology into Bioclinica's clinical trial imaging and data management solutions, enhancing patient monitoring and improving data quality. Furthermore, regulatory challenges present a significant obstacle to the widespread adoption of AI technologies in clinical trials. The complexities of integrating AI into the trial process raise concerns regarding data privacy and security, as sensitive patient information is involved. Regulatory bodies must establish clear guidelines and standards for AI-powered solutions to ensure data integrity, patient safety, and keeping with existing regulations.

By Phase

  • Phase-I
  • Phase-II
  • Phase-III

By Application

  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases or Conditions
  • Metabolic Diseases
  • Infectious Diseases
  • Others

By End-use

  • Pharmaceutical Companies
  • Academia
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to these factors including high R&D investments, increasing adoption of technically advanced solutions, presence of key players, and their efforts to develop newer patents. It is attributed to the presence of several AI-based start-ups in the region, further driving the target market over the forecast period. For instance, Bullfrog AI is a U.S.-based start-up developing bfLEAP, a proprietary AI platform for precision medicine. Furthermore, the rising awareness of AI-based technologies and their adoption to enhance drug trial outcomes is propelling the market growth in the region. Government initiatives and increasing strategic initiatives by major players are among a few factors driving the region's demand for AI-based clinical trial solutions.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the AI-based Clinical Trials Solution Provider Market By Phase, By Application, By End-use and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Phase launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   AI-based Clinical Trials Solution Provider Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of AI-based Clinical Trials Solution Provider Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   AI-based Clinical Trials Solution Provider Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   AI-based Clinical Trials Solution Provider Market, By Phase Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Phase-I
        2. Phase-II
        3. Phase-III

  • 8.   AI-based Clinical Trials Solution Provider Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
        2. Cardiovascular Diseases
        3. Neurological Diseases or Conditions
        4. Metabolic Diseases
        5. Infectious Diseases
        6. Others

  • 9.   AI-based Clinical Trials Solution Provider Market, By End-use Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical Companies
        2. Academia
        3. Others

  • 10.   North America AI-based Clinical Trials Solution Provider Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America AI-based Clinical Trials Solution Provider Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe AI-based Clinical Trials Solution Provider Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific AI-based Clinical Trials Solution Provider Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Phases Offered and Financial Layouts)
    •   1. Unlearn.AI, Inc.
         1.1. Company Overview
         1.2. Phase Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Saama Technologies
         2.1. Company Overview
         2.2. Phase Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Antidote Technologies, Inc.
         3.1. Company Overview
         3.2. Phase Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Phesi
         4.1. Company Overview
         4.2. Phase Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Deep 6 AI
         5.1. Company Overview
         5.2. Phase Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Innoplexus
         6.1. Company Overview
         6.2. Phase Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Mendel.ai
         7.1. Company Overview
         7.2. Phase Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Intelligencia
         8.1. Company Overview
         8.2. Phase Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Median Technologies
         9.1. Company Overview
         9.2. Phase Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Symphony AI
         10.1. Company Overview
         10.2. Phase Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. BioAge Labs, Inc.
          11.1. Company Overview
          11.2. Phase Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. AiCure, LLC
          12.1. Company Overview
          12.2. Phase Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. CONSILX
          13.1. Company Overview
          13.2. Phase Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. DEEP LENS AI
          14.1. Company Overview
          14.2. Phase Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Halo Health Systems
          15.1. Company Overview
          15.2. Phase Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Pharmaseal
          16.1. Company Overview
          16.2. Phase Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Ardigen
          17.1. Company Overview
          17.2. Phase Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
         18. Trials.Ai
          18.1. Company Overview
          18.2. Phase Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
         19. Koneksa Health
          19.1. Company Overview
          19.2. Phase Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
         20. Euretos
          20.1. Company Overview
          20.2. Phase Portfolio
         20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview
         21. BioSymetrics
          21.1. Company Overview
          21.2. Phase Portfolio
          21.3. SWOT Analysis
          21.4. Financial Overview
          21.5. Strategic Overview
         22. Google- Verily
          22.1. Company Overview
          22.2. Phase Portfolio
          22.3. SWOT Analysis
          22.4. Financial Overview
          22.5. Strategic Overview
         23. GNS Healthcare
          23.1. Company Overview
          23.2. Phase Portfolio
          23.3. SWOT Analysis
          23.4. Financial Overview
          23.5. Strategic Overview
         24. IBM Watson
          24.1. Company Overview
          24.2. Phase Portfolio
          24.3. SWOT Analysis
          24.4. Financial Overview
          24.5. Strategic Overview
         25. Exscientia
          25.1. Company Overview
          25.2. Phase Portfolio
          25.3. SWOT Analysis
          25.4. Financial Overview
          25.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients